Insider Buying: Healius (ASX:HLS) Insider Purchases 54,431 Shares of Stock

Healius Limited (ASX:HLS) insider Paul Anderson bought 54,431 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were bought at an average cost of A$0.88 per share, with a total value of A$47,899.28.

Paul Anderson also recently made the following trade(s):

• On Friday, October 31st, Paul Anderson purchased 57,471 shares of Healius stock. The stock was purchased at an average cost of A$0.89 per share, for a total transaction of A$50,976.78.

Healius Price Performance

The company has a debt-to-equity ratio of 153.54, a quick ratio of 0.47 and a current ratio of 0.50. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -2.54, a price-to-earnings-growth ratio of -0.94 and a beta of 0.73.

Healius Company Profile

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands.